She noted that glitazones- a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance-
have all shown initial promise in clinical trials before worrisome side effects began to surface in users(Avandia was recently withdrawn from the U.S. market due to heart risks).